Intercell AG and CSL Ltd. sign Exclusive Agreement for Marketing and Distribution of Japanese Encephalitis Vaccine

01-Sep-2005

Intercell AG announced the signature of an exclusive agreement with CSL Ltd. for the Marketing and Distribution of Intercell´s novel cell culture based Japanese encephalitis vaccine in Australia. It is Intercell's first commercialization agreement for the future delivery of its lead vaccine product which is planned to enter Phase III clinical trials in September 2005.

In order to optimally market the vaccine in Australia where the disease is endemic, Intercell has been seeking for a strong local strategic partner. Under the terms of this agreement CSL Ltd. receives the sole and exclusive marketing and distribution rights of Intercell´s novel prophylactic vaccine against Japanese encephalitis in Australia, New Zealand, Papua New Guinea and Pacific Islands.

Intercell is planning to market the product independently from this agreement with CSL Ltd. in the United States and Europe targeting the travelers and armed forces market to replace current suboptimal vaccines produced on mouse brain. The production of the vaccine will be performed at Intercell´s facility in Livingston, Scotland.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance